MedPath

Mercaptopurine

Generic Name
Mercaptopurine
Brand Names
Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
Drug Type
Small Molecule
Chemical Formula
C5H4N4S
CAS Number
50-44-2
Unique Ingredient Identifier
PKK6MUZ20G
Background

An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

Indication

For remission induction and maintenance therapy of acute lymphatic leukemia.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Clinical Trials
Related News

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting
Conditions
Philadelphia-Positive ALL
Lymphoblastic Leukemia
Adult ALL
Interventions
Procedure: allogeneic stem cell transplantation
Procedure: Total body irradiation
First Posted Date
2023-12-19
Last Posted Date
2023-12-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
150
Registration Number
NCT06175702

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 3
Not yet recruiting
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Radiation: Radiation Therapy
First Posted Date
2023-11-09
Last Posted Date
2025-04-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
680
Registration Number
NCT06124157

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Recruiting
Conditions
Acute Lymphoid Leukemia
Minimal Residual Disease
Gene Abnormality
Chemotherapeutic Toxicity
Interventions
Drug: Intrathecal Suspension
First Posted Date
2023-07-25
Last Posted Date
2025-05-07
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Target Recruit Count
180
Registration Number
NCT05959720
Locations
🇧🇷

Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

First Posted Date
2023-05-08
Last Posted Date
2025-05-11
Lead Sponsor
Tanja Andrea Gruber
Target Recruit Count
90
Registration Number
NCT05848687
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 22 locations

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

First Posted Date
2022-12-21
Last Posted Date
2023-03-03
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
100
Registration Number
NCT05660473
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

First Posted Date
2022-12-09
Last Posted Date
2025-03-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
27
Registration Number
NCT05645718
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1
Recruiting
Conditions
Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
Interventions
First Posted Date
2022-08-18
Last Posted Date
2022-08-18
Lead Sponsor
University Hospital, Antwerp
Target Recruit Count
10
Registration Number
NCT05506332
Locations
🇧🇪

University Hospital Antwerp, Edegem, Antwerp, Belgium

🇧🇪

AZ Delta, Roeselare, West Vlaanderen, Belgium

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

First Posted Date
2022-03-31
Last Posted Date
2025-04-02
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
68
Registration Number
NCT05303792
Locations
🇺🇸

University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

🇺🇸

Oregon Health and Science University, Portland, Oregon, United States

🇺🇸

Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States

and more 69 locations

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

First Posted Date
2022-01-14
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
35
Registration Number
NCT05192889
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

First Posted Date
2021-12-15
Last Posted Date
2025-05-08
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
24
Registration Number
NCT05157971
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy